Exelixis Stock News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

These two companies have moved in opposite directions this year.

Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.

Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Successful money managers piled into these fast-growing companies in the first quarter.

Successful money managers piled into these fast-growing companies in the first quarter.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.

They have one key common denominator.

They have one key common denominator.

This biotech stock has been on fire since the beginning of the year.

Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blo

Smart Beta ETF report for XBI